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Background. The National Institute for Quality and
Efficiency in Health Care (IQWiG) employs an efficiency
frontier (EF) framework to facilitate setting maximum
reimbursable prices for new interventions. Probabilistic
sensitivity analysis (PSA) is used when yes/no reimburse-
ment decisions are sought based on a fixed threshold. In
the IQWiG framework, an additional layer of complexity
arises as the EF itself may vary its shape in each PSA iter-
ation, and thus the willingness-to-pay, indicated by the
EF segments, may vary. Objectives. To explore the prac-
tical problems arising when, within the EF approach,
maximum reimbursable prices for new interventions are
sought through PSA. Methods. When the EF is varied in
a PSA, cost recommendations for new interventions
may be determined by the mean or the median of the dis-
tances between each intervention’s point estimate and
each EF. Implications of using these metrics were
explored in a simulation study based on the model
used by IQWiG to assess the cost-effectiveness of 4 anti-
depressants. Results. Depending on the metric used,
cost recommendations can be contradictory. Recommen-
dations based on the mean can also be inconsistent.
Results (median) suggested that costs of duloxetine, ven-
lafaxine, mirtazapine, and bupropion should be
decreased by e131, e29, e12, and e99, respectively. These
recommendations were implemented and the analysis
repeated. New results suggested keeping the costs as
they were. The percentage of acceptable PSA outcomes
increased 41% on average, and the uncertainty associ-
ated to the net health benefit was significantly reduced.
Conclusions. The median of the distances between every
intervention outcome and every EF is a good proxy for the
cost recommendation that would be given should the EF
be fixed. Adjusting costs according to the median
increased the probability of acceptance and reduced
the uncertainty around the net health benefit distribu-
tion, resulting in a reduced uncertainty for decision mak-
ers. Key words: detailed methodology: probabilistic
sensitivity analysis; simulation methods; decision analy-
sis. (Med Decis Making 2017;37:162–172)
In the German system of statutory healthinsurance—covering approximately 90% of the
German population—the assessment of the benefits
and costs of drugs was legislated as a remit for the
National Institute for Quality and Efficiency in
Health Care (IQWiG) in 2007 (see Social Code Book
[SGB] V § 35b). To comply with the legislative stip-
ulation, IQWiG published its general methods for
the assessment of the relation between benefits and
costs after extensive consultations in 2009.1 At the
core, an efficiency frontier framework was intro-
duced. In IQWiG’s efficiency frontier approach, ex-
isting therapies (interventions) for a given health
problem are plotted in a cost-effectiveness plane,
with intervention costs per patient on the x-axis
and outcomes (measured, for instance, as quality-
of-life scores) on the y-axis. An example of this
can be seen in Figure 1. The enveloping line and
its extrapolation to the right is called the efficiency
frontier. New interventions that locate themselves
to the right and below the frontier may prima facie
be judged as unduly costly relative to the benefits
they provide. With such interventions, IQWiG seeks
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price reductions such that the interventions move to
the frontier. The approach assists in defining indica-
tion-specific willingness-to-pay thresholds,2
expressly avoiding fixed thresholds (for the legal
and political reasons motivating the methodological
choice, see Gerber-Grote et al.3 and Sandmann et al.4
and the references therein). The detailed setup of an
efficiency frontier within the German5 and other set-
tings6–14 has been described elsewhere. The effi-
ciency frontier is also used in Belgium to select an
appropriate comparator15 and in France to calculate
incremental cost-effectiveness ratios for nondomi-
nated interventions.16 Even though the scope of
these efficiency frontiers differs from the objective
of IQWiG’s, there are similar challenges (e.g., those
concerning how to account for uncertainty in the
efficiency frontier framework).
In November 2013, the first assessment of costs
and effects of new drugs within one therapeutic
area was published by IQWiG. This was the assess-
ment of 4 drugs in the indication of depression.17
At the time when the commission was assigned in
December 2009 by the Federal Joint Committee, ven-
lafaxine, for instance, was considered a fairly new
drug that had additional benefit over its comparators
at comparatively high costs. For this article, the case
is only of illustrative nature. It should be emphasized
that the original efficiency frontier concept did not
deal with uncertainty, but in the IQWiG assessment
of depression, uncertainty was explicitly explored.
While assessing these costs and effects through
a health economic model (based on the methods
guide1), a potential methodological problem arose,
relating to the analyses of uncertainty through a
probabilistic sensitivity analysis (PSA). The PSA
accounts for the uncertainty around input values
for the model and leads to a set of possibly highly
varying combinations of costs and effects on the
cost-effectiveness plane.7,18 PSAs are commonly
usedwhen a yes/no reimbursement decision is sought
based on a fixed threshold, like in the UK National
Institute for Health and Care Excellence (NICE)
setting.
Given the uncertainty around the estimates of
costs and/or effects of existing therapies, the effi-
ciency frontier is actually not known as a precisely
deterministic line on the cost-effectiveness plane.
Since the location of new interventions on the cost-
effectiveness plane is also uncertain, the horizontal
distance between the new intervention and the effi-
ciency frontier (i.e., the difference between actual
and required cost per patient) will vary per PSA sim-
ulation. Thus, in the efficiency frontier framework,
an additional layer of complexity arises compared
with the fixed-threshold framework as the efficiency
frontier itself is also probabilistic in practice, and the
method used to address the problem when the effi-
ciency frontier is deterministic does not directly
apply in the probabilistic setting. Therefore, before
IQWiG could formally move from a deterministic to
a probabilistic approach (in case IQWiG decides to
do this), this issue needs to be resolved; otherwise,
there is no alternative approach for the current deter-
ministic one.When this problem is solved, any views
on whether decision making should rely on deter-
ministic or probabilistic outcomes can be based on
principles rather than practicalities. However, this
article does not deal with this underlying question.
In this article, we first explain how cost recom-
mendations for new interventions in the efficiency
frontier framework should be determined when
uncertainty around model outcomes is taken into
consideration through a PSA. It is important to stress
that cost recommendations are given for new inter-
ventions only, and such recommendations are given
as an output of a PSA (i.e., after a PSA is run). In
a PSA, the position of the cost and effect estimates
of the treatments that form the efficiency frontier
will vary on the cost-effectiveness plane due to the
uncertainty around those estimates, but no further
Figure 1 Probabilistic sensitivity analysis (PSA) outcomes and
cost adjustment. TZA, tricyclic antidepressants.
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cost recommendation for the treatments that form the
efficiency frontier will be given in any way. Then, we
describe and present the results of a simulation study
that was set up to illustrate the practical problems
encountered when the efficiency frontier is probabi-
listic. This simulation is based on the model devel-
oped by a group of experts in cooperation with
IQWiG to assess the cost-effectiveness of antidepres-
sants.17 In a large number of PSA simulations, some
results (i.e., the horizontal distance between the
new intervention and the efficiency frontier) may be
extreme. In that situation, the median is theoretically
a better measure of central tendency than the mean.
We demonstrate the difference between the perfor-
mance of the two and the implications in cost recom-
mendations within IQWiG’s efficiency frontier
framework.
Cost Recommendation under Uncertainty
in IQWiG’s Efficiency Frontier
Simply speaking, the main aim of the efficiency
frontier is to determine an appropriate price for new
interventions within the German system of statutory
health insurance. When a new intervention is below
the efficiency frontier, its cost must be reduced so
that it becomes acceptable by bringing it exactly to
the efficiency frontier. This implies that the location
of the new intervention on the cost-effectiveness
plane might only be modified horizontally—that is,
the benefits are considered to be given, but the cost
could be adjusted (in this case reduced), for example,
by the intervention’s manufacturer. (The cost reduc-
tion [or increase] mentioned here is not equal to the
price reduction for a given intervention as reported
in the cost-effectiveness evaluation of antidepres-
sants by IQWiG.1 However, there is a [linear] relation-
ship between the price of the new intervention and
the total cost associated to it so that when the cost
reduction is known, the price reduction should be
easily calculated. Since this relationship was
unknown to us, we present all the results in terms
of cost instead of price.) This idea is illustrated in Fig-
ure 1, where the efficiency frontier is determined by
placebo, tricyclic antidepressants (TZA [Trizyklische
Antidepressiva in German]), and agomelatine, and
the outcomes, labeled 1 to 6, are the results of PSA
iterations on the new intervention. (All tricyclic anti-
depressants plus maprotiline were considered as
a drug class in the preceding benefit assessments per-
formed by IQWiG.19,20 If no heterogeneity could be
detected for these drug classes, lead compounds
were determined as representatives of drug classes.)
The outcomes for the new intervention, labeled 1,
2, and 3, are not accepted unless their costs are
reduced by e77 (A), e131 (B), and e130 (C), respec-
tively. Note that different segments of the efficiency
frontier are used to determine the cost reduction.
Likewise, when a new intervention is located above
the efficiency frontier, its cost is considered appropri-
ate. However, given its level of benefits, a higher cost
(determined by its horizontal distance to the effi-
ciency frontier) may also be acceptable. For example,
the cost of the outcomes for the new intervention,
labeled 4, 5, and 6 in Figure 1, could be increased
by e150 (D), e175 (E), and e290 (F), respectively,
and still be considered appropriate. Note finally
that the cost of a new intervention does not need to
change if it lies on a segment of the efficiency frontier,
since the tradeoff between costs and benefits, as stip-
ulated by this segment, is in the IQWiG context often
considered a willingness-to-pay in a given field of
indication.
When a PSA is now performed, not only the point
estimate of the new intervention changes but also
those of all comparators on the cost-effectiveness
plane, resulting in as many different efficiency fron-
tiers as PSA iterations. Depending on its position rel-
ative to the efficiency frontier, a cost reduction or
increase for the new intervention may be considered.
For didactic reasons, we keep the efficiency fron-
tier fixed in a first series of PSA iterations where
only the position of the new intervention changes.
It is important to emphasize that the distance
between the average point estimate of the new inter-
vention and the efficiency frontier (further referred
to as metric M1) is not necessarily the same as the
average of the distances between every single PSA
outcome of the new intervention and the fixed effi-
ciency frontier. Furthermore, if the latter is used to
determine a cost reduction or increase, it may lead
to erroneous decisions. We will explain this with
the help of Figure 1. As indicated above, we assume
a fixed efficiency frontier, while the outcomes
labeled 1 to 6 are the results of PSA iterations on
the new intervention. The average of the 6 point esti-
mates of the new intervention (solid square) lies
below the efficiency frontier, and thus the new inter-
vention would be rejected and the horizontal dis-
tance M suggests a e75 cost reduction. However,
when computing all the individual distances
between the PSA outcomes 1 to 6 and the efficiency
frontier, we get cost reductions A (e77), B (e131),
and C (e130) and cost increases D (e150), E (e175),
and F (e290). On average, this would suggest a e46
cost increase, which contradicts the e75 cost
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reduction suggested by the distance M. A cost
increase would keep the average point estimate of
the new intervention below the efficiency frontier
and may decrease the probability of accepting the
new intervention since some of the outcomes located
to the left of the efficiency frontier may move to the
right of the efficiency frontier and become rejected.
It should be emphasized that to appropriately repre-
sent uncertainty within the efficiency frontier, 2 dis-
tinctive yet simultaneously occurring aspects of
uncertainty must be accounted for in each iteration
of a PSA. First, the new interventionmay vary its posi-
tion on the cost-effectiveness plane (as shown in Fig-
ure 1), and second, all other treatment strategies may
vary their position on the cost-effectiveness plane as
well. Because of the latter, the efficiency frontier
may vary its shape, and crucially, the tradeoff between
costs and effects (willingness-to-pay) as indicated by
the segments of the efficiency frontier may vary
between each iteration of the PSA. Therefore, in the
case of a probabilistic efficiency frontier, metric M1
cannot be computed. We can only compute the dis-
tance fromeveryPSAoutcomeof the new intervention
and the efficiency frontier generated in this particular
PSA iteration. The average of these individual distan-
ces will be referred to as metric M2. A practical prob-
lem now is that the distribution of the individual
distances is skewed (and may have extreme values).
Because of that, if price recommendations were based
on M2, it may result in a biased estimation of the real
recommended price. In cases of skewed distributions
with heavy tails, statistical theory suggests that
a median (here of the individual distances; further
referred to as metric M3) is a better statistic than M2
to represent the typical value of the distance from
aPSAoutcomeof the new intervention to the PSAout-
come of the efficiency frontier.21 This issue was
studied with a simulation study based on the model
developed by IQWiG to assess the cost-effectiveness
of antidepressants.17
METHODS
We set up a simulation study to assess cost recom-
mendations based on PSA that was based on the
model developed by IQWiG to assess the cost-
effectiveness of antidepressants.17 The assumptions
wemade in our simulations analyses are summarized
in Table 1.
We used as a data set the results of the PSA
described in the cost-effectiveness evaluation of anti-
depressants by IQWiG,17 which is the result of
100,000 PSA iterations. An example of the first 4 con-
figurations of the cost-effectiveness plane can be seen
in Figure 2. In each iteration, a new efficiency frontier
and a point estimate (costs and benefits) of 4 new
interventions (i.e., venlafaxine, duloxetine, bupro-
pion, and mirtazapine) were generated. Therefore,
the average point estimate for costs and benefits and
the cost increase or reduction needed to bring that
average to the efficiency frontier could not be com-
puted here as there is no single (deterministic) effi-
ciency frontier. Hence, we computed the average
and the median of the individual distances between
each intervention point estimate and each efficiency
frontier (metrics M2 and M3, respectively) and stud-
ied the implications when cost recommendations
would be based on each of these 2 metrics.
RESULTS
In all PSA iterations, placebo was the first element
on the efficiency frontier (cheapest and with lowest
Table 1 Simulation Assumptions
Assumptions
1. The newhealth care intervention does not need to lower the efficiency of the relevant therapeutic area. Thus, any possible
outcomes for the new intervention were allowed on the cost-effectiveness plane so that all the areas below and above the
efficiency frontier were used.
2. We have considered a general situation where the first intervention included on the efficiency frontier (the one with the
lowest costs and benefits) was not placed at (0, 0) on the cost-effectiveness plane.
3. We have assumed that the costs of the new intervention were always positive and the benefits were constrained between
zero and 1.
4. We considered placebo as ‘‘doing nothing.’’ Thus, when the first intervention included on the efficiency frontier was
placebo, every value of a new intervention providing less benefit than placebo was considered unacceptable (i.e., it would
be unethical to ‘‘do something’’ as opposed to ‘‘do nothing’’ so that the patient loses health, even if it leads to cost saving).
5. We assumed that there are at least 2 interventions determining the efficiency frontier. Thus, we did not consider the
situation where only 1 intervention could be plotted.
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benefits). Most of the PSA iterations resulted in an
efficiency frontier with 2 (75%) and 3 (21.64%)
interventions. The most common efficiency frontiers
were placebo-TZA and placebo-TZA-agomelatine.
Details on the number of interventions per PSA
iteration and the position of each intervention on
the efficiency frontier can be seen in Table 2, and fur-
ther descriptive statistics are shown in Table 3. The
maximum
willingness-to-pay threshold, which is determined
by the last program on the efficiency frontier, is com-
puted as 1 divided by the slope of the last segment on
the efficiency frontier. Thus, the average of these
100,000 estimates of the maximum willingness-to-
pay was equal to e4.1*1013, whereas the median
was e237 (cf. Table 3). Note that this average is
extremely high due to the PSA iterations where the
slope of the last segment was nearly zero. However,
Figure 2 Probabilistic sensitivity analysis (PSA) samples with probabilistic efficiency frontier. TZA, tricyclic antidepressants.
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this average does not correspond to the standard def-
inition of a probabilistic incremental cost-effective-
ness ratio (ICER) as DC / DE, where DC and DE
denote the average incremental costs and effects,
respectively, which should be closer to the median.
Results regarding acceptance and cost recommen-
dations have been summarized in Table 4. For all the
new interventions, the percentage of acceptable PSA
outcomes (above the efficiency frontier) was low,
with 13.92% for venlafaxine being the highest. Mirta-
zapine had a similar percentage of acceptance
(12.22%), but for duloxetine and bupropion, these
were almost zero.
In the original data set, the average cost of duloxe-
tine, venlafaxine, mirtazapine, and bupropion was
e408, e319, e295, and e372, respectively. Depending
Table 2 Number of Interventions and Their Position on the Efficiency Frontier
No. of Interventions on
the Efficiency Frontier No. of PSA Iterations Intervention
Position on the Efficiency Frontier
First Second Third Fourth Fifth
1 0 Placebo 100,000 0 0 0 0
2 75,040 TZA 0 94,913 4185 0 0
3 21,645 SSRI minimum 0 5086 0 0 0
4 3276 Trazodone 0 1 228 63 0
5 39 Agomelatine 0 0 20,498 3252 39
6 0 SSRI maximum 0 0 49 0 0
PSA, probabilistic sensitivity analysis; SSRI, selective serotonin reuptake inhibitor; TZA, tricyclic antidepressants.
Table 3 Descriptive Statistics for the Slope of the Segments of the Efficiency Frontier
and the Associated Willingness-to-Pay
n Average Median 2.5th Percentile 97.5th Percentile Minimum Maximum
Slope last segment 100,000 0.0035 0.0042 0.00002 0.0064 3*10218 0.0091
Willingness-to-pay (l), e 100,000 4.1*1013 237 156 40,022 109 3*1017
Slope segment 1 100,000 0.0043 0.0043 0.0025 0.0064 0.0007 0.0091
Willingness-to-pay 1, e 100,000 242 231 155 395 109 1314
Slope segment 2 24,960 0.0004 0.0001 0.000006 0.0028 0 0.0042
Willingness-to-pay 2, e 24,960 35,527 5713 344 146,634 237 N
Slope segment 3 3315 0.0002 0.0002 0.00001 0.0006 0.0000003 0.0016
Willingness-to-pay 3, e 3315 13,817 4136 1440 76,630 607 2,692,600
Slope segment 4 39 0.0001 0.0001 0.00002 0.0005 0.00001 0.0005
Willingness-to-pay 4, e 39 13,700 6795 1950 47,567 1813 74,956
Table 4 Percentage of Acceptance and Cost Recommendations Based on Metrics M2 and M3
Before Implementing Cost Recommendation After Implementing Cost Recommendation (Based on the Median M3)
Acceptance, %
Cost Recommendation, e
Acceptance, %
Cost Recommendation, e
M2 M3 M2 M3
Duloxetine 0.28 2128 2131 49.65 3 0
Venlafaxine 13.92 33 229 48.67 62 0
Mirtazapine 12.22 1 212 47.96 13 0
Bupropion 0.10 299 299 43.81 0 21
A negative monetary valuemeans cost reduction, whereas a positive onemeans cost increase. M2, average of the cost recommendations based on the prob-
abilistic sensitivity analysis (PSA) outcomes separately; M3, median of the cost recommendations based on the PSA outcomes separately.
*Simulations providing an infinite cost increase were excluded from the computation of the average (16 for duloxetine, 49 for venlafaxine, 30 for mirtaza-
pine and 2 for bupropion).
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on the metric used, cost recommendations based on
M2 and M3 can be contradictory, as occurred here,
especially with venlafaxine and to a lower extent
with mirtazapine. This is because the distribution
of the individual distances between PSA outcomes
of the new intervention and the PSA efficiency fron-
tiers is most asymmetric for venlafaxine. In that case,
recommending a cost increase for both venlafaxine
(e33) andmirtazapine (e1) does not seem appropriate
since this, for example, would decrease the percent-
age of acceptable PSA outcomes. Moreover, if this
cost increase was implemented andM2 recalculated,
the updated recommendation based on M2 would
result in a cost decrease since the recalculated
M2 would be negative. Based on the average M2,
the cost of duloxetine and bupropion should be
decreased by e128 and e99, which are similar to those
recommended by the median M3. However, the sim-
ulations providing a (numerically) infinite distance
(or equivalently an infinite cost increase) were
excluded from the computation of the average M2,
and therefore the cost recommendation based on
M2 shown in Table 4 is likely to be an underestima-
tion. Based on the median of the distances between
every PSA outcome and every efficiency frontier
(M3), these simulations are also included, and as
explained above, the median is more representative
of the typical observation than the average, and it is
the preferred measure of central tendency of the pop-
ulation under study. Thus, based on the simulation
results, the cost of duloxetine, venlafaxine, mirtaza-
pine, and bupropion should be decreased by e131,
e29, e12, and e99, respectively, as recommended by
the median M3.
We implemented the cost recommendations based
on themedian and repeated the analysis. An example
of the first 4 configurations after implementing the
cost recommendations can be seen in Figure 3. We
can observe that comparedwith Figure 2, the position
of the new interventions has been simply shifted
toward the efficiency frontier.
The results after the cost recommendations based
on the median were implemented (see Table 4)
showed that the percentage of acceptable PSA out-
comes increased significantly, with 43.81% for
bupropion being the lowest and 49.65% for duloxe-
tine being the highest. The average cost of duloxe-
tine, venlafaxine, mirtazapine, and bupropion was
now e277, e290, e283, and e273, respectively (i.e.,
the cost before recommendation minus the recom-
mended reduction). Updated recommendations
based on the median (M3), as expected, were e0
(except for bupropion, which was –e1, but this
may be caused by rounding up the costs). Note
finally that if updated recommendations were based
on the average M2, this would imply a cost increase
for all interventions (except for bupropion), which
would imply returning to the situation before
update, which is clearly worse than the situation
after implementing cost recommendations based
on the median.
Moreover, we have also observed that the uncer-
tainty associated with the net health benefit (NHB)
has been reduced after implementing the cost recom-
mendation, as can be seen in Figure 4. Note that the
NHB was graphically defined as the vertical distance
between a point estimate and the last segment (or its
extension—backward or forward) on the efficiency
frontier.5 Thus, it is not only that there are many
more PSA outcomes above the efficiency frontier
but also that the PSA outcomes are closer to the last
segment on the efficiency frontier (for that reason,
we observed that the distribution of the NHB after
implementing the cost recommendations is centered
at zero). Since inmost of the cases, the efficiency fron-
tier had exactly one segment (around 75%), it also
means that the PSA outcomes are in fact closer to
the efficiency frontier. As can be seen in Figure 4,
most of the PSA outcomes for the new intervention
were originally located to the right of the efficiency
frontier, where the NHB is negative. If the original
distribution of the PSA outcomes had laid more
across the frontier, the effect of implementing the
cost recommendation on theNHB distributionwould
have been smaller.
DISCUSSION
In this article, we have explored the potential prob-
lems and some solutions arising when, within the
IQWiG efficiency frontier approach, a maximum
reimbursable price for a new intervention is sought
through probabilistic sensitivity analyses. Cost rec-
ommendations on the efficiency frontier seem to be
prone to skewed distributions. In these situations,
statistical theory says that the median is a better mea-
sure of central tendency than the mean, and for price
negotiations within a probabilistic efficiency frontier
framework, this should be noted. To our knowledge,
this issue was never raised in the field of health
economics.
We have first explained that when the efficiency
frontier is deterministic, cost recommendations
should be based on the average point estimate of the
PSA outcomes of the new intervention. An increase
CORRO RAMOS AND OTHERS
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or decrease in cost recommendation is then calcu-
lated as the horizontal distance between the average
point estimate and the efficiency frontier (metric
M1). In general, thismetric is not the same as the aver-
age of the distances between every PSA outcome and
the efficiency frontier (metric M2). In fact, we have
observed that metric M2 was always larger than met-
ric M1. This is because the distribution of metric M2
was affected by very large values.
When the efficiency frontier is probabilistic (i.e., it
alters its shape in each PSA iteration), cost recom-
mendations cannot be based on the distance between
the average point estimate of the PSA outcomes and
the efficiency frontier (metric M1) since this cannot
be computed. Based on the results obtained when
the efficiency frontier is deterministic (results not
shown), we expected that the median M3 should be
preferred over the average M2 when the efficiency
Figure 3 Probabilistic sensitivity analysis (PSA) samples with probabilistic efficiency frontier after implementing cost recommendations.
TZA, tricyclic antidepressants.
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frontier is probabilistic. In this situation, theory con-
firms that themedian (metricM3) is more representa-
tive of the typical observation than the average
(metric M2), and it is the preferredmeasure of central
tendency of the population under study (see, e.g.,
Ross,21 Section 3.3). With our simulation analysis,
we could demonstrate that also in this case, the
median M3 is in general better than M2. Moreover,
when calculating the distances between every PSA
outcome and every efficiency frontier, we found
that for all the new interventions, some simulations
provided a (numerically) infinite distance (or equiva-
lently a numerically infinite cost increase). Note that
this is due to the PSA iterationswhere the slope of the
last segment was nearly zero. This also has implica-
tions in the maximum willingness-to-pay threshold
(which is computed as 1 divided by the slope of the
last segment on the efficiency frontier) and therefore
in measures like the net health or monetary benefit,
since the average willingness-to-pay can be (numeri-
cally) infinite. In this case, the median also provides
a better estimate, as shown inTable 3. Descriptive sta-
tistics for each segment separately are also presented
in Table 3. That way, we can observe what the contri-
bution of each segment to the maximumwillingness-
to-paymight be. This illustrates that, as expected, the
distribution of the cost recommendations based on
the PSA outcomes separately can be highly skewed
and affected by the presence of extreme values.
Note that such extreme values are not statistical out-
liers in a formal sense. An outlier can be defined as an
observation that is very different from other observa-
tions in a set of collected data. Given a skewed distri-
bution with heavy tails and/or a rather small sample
size, a single outlier may heavily affect the sample.
In our simulation, we do have simulated model out-
comes that heavily affect the mean of the distances
as they resulted in infinite distances. We have seen
that this happens often in the PSA, even though the
PSA size was very large (10,000). Therefore, we may
assume that the median (metric M3) instead of the
average (metricM2) should be used to determine price
recommendations in this setting. The average (metric
M2) would overestimate the cost recommendation,
which can be very wrong. The median (metric M3) is
less sensitive to skeweddistributions and extreme val-
ues, and when the efficiency frontier is probabilistic,
cost recommendations should be based on it.
Our analysis has also confirmed that the median
M3 is a good proxy for the cost recommendation
that would be given should the efficiency
frontier be fixed. After implementing the cost recom-
mendations based on the median, we have seen that
the ‘‘updated’’ cost recommendation was e0, but
also the probability of acceptance increased substan-
tially, which would not occur if M2 would be used to
recommend the costs. Note that the percentage of
acceptable PSA outcomes is expected to be close to
50% as a consequence of the cost being reduced by
themedian. The fact that the percentage is not exactly
50% in all cases is due to the efficiency frontier hav-
ing more than one segment in some of the PSA itera-
tions. On top of that, the NHB distribution became
narrower, which would result in a reduced uncer-
tainty for the decision maker.
IQWiG’s general methods in its current form22 do
not go into the question addressed in this article.
Applying the median of the distances between each
intervention point estimate and each efficiency fron-
tier after PSA will be incorporated as a specification
in the next version of IQWiG’s methods. Prima facie,
Belgium and France will not run into this problem as
they do not use the efficiency frontier to determine
prices. However, even if one wants to simply decide
which of 2 comparators dominates another and thus
forms the efficiency frontier, one might encounter
the problem in a PSA if the mean and the median
lies on 2 sides of the efficiency frontier. Therefore,
this simulation is of assistance to anyone using the
efficiency frontier.
The choice of the probability distributions for the
input parameters in health economic models is a cru-
cial step when performing a PSA. However, since
PSA is a well-established method, in this article, we
are not explaining how to perform it properly (see,
e.g., Briggs7). In the current study, we used the simu-
lated costs and benefits for all treatments, implicitly
assuming that the PSA that generated these outcomes
was performed in a standard and proper way. Details
about how the PSA was performed can be found in
the cost-effectiveness evaluation of antidepressants
by IQWiG (Table 81).17 Thus, the way the PSA out-
puts are generated is not related to the choice between
the mean and the median of the distances as a way to
determine cost recommendations but to the validity
of the estimates. Obviously, if the PSA is not per-
formed correctly, the median and the mean of the
distances would not be reliable estimates, but never-
theless, even in that case, we would always choose
the median of the distances over the mean.
Finally, note that we had always at least one seg-
ment in the efficiency frontier to determine the
needed or allowed costs. This will not generally be
the case, as can be observed in the cost-effectiveness
evaluation of antidepressants performed by IQWiG.17
Here, various situations (depending on scenario and
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outcome used) occur where placebo dominates all
current intervention options. In such situation, there
is no clear decision rule to state which outcomes are
acceptable, as there is no revealed willingness-to-
pay. An overarching question in this context, but
beyond the scope of this article, is how to determine
that a number of therapies are sufficient in a given
area to provide a useful frontier.2 Hence, how to
deal with those scenarios should be the subject of fur-
ther discussion.
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